Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | THRB | P10828 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24121640 | 0.73 | MEN1 (0.68) | MEN1KMT2AKDM4EMAPTALDH1A1 | |
| SCHEMBL24394783 | 0.72 | GAA (0.48) | MEN1KMT2ACYP3A4MAPTALDH1A1 | |
| SCHEMBL21045982 | 0.70 | MEN1 (0.57) | MEN1KMT2AKDM4EMAPTALDH1A1 | |
| SCHEMBL21045983 | 0.70 | MEN1 (0.57) | MEN1KMT2AKDM4EMAPTALDH1A1 | |
| SCHEMBL21074925 | 0.69 | KDM4E (0.40) | MEN1KMT2ATHRBKDM4EMAPT | |
| SCHEMBL21074872 | 0.69 | MEN1 (0.41) | MEN1KMT2ATHRBCYP3A4HPGD | |
| SCHEMBL24121622 | 0.69 | MEN1 (0.73) | MEN1KMT2AMAPTIDH1GAA | |
| SCHEMBL10019489 | 0.69 | KMT2A (1.00) | MEN1KMT2AKDM4EMAPTL3MBTL1 | |
| SCHEMBL24121638 | 0.68 | KMT2A (0.55) | MEN1KMT2ACYP3A4ALDH1A1MAPK1 | |
| SCHEMBL21074924 | 0.68 | LMNA (0.42) | MEN1KMT2ACYP3A4HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12357589-B2 | Inhibitors of Bunyaviridae and uses thereof | SAINT LOUIS UNIVERSITY (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250009686-A1 | INHIBITORS OF BUNYAVIRIDAE AND USES THEREOF | SAINT LOUIS UNIVERSITY (US) | 2025-01-09 | — | — | US | disclosed |
| US-12121500-B2 | Inhibitors of Bunyaviridae and uses thereof | SAINT LOUIS UNIVERSITY (US) | 2024-10-22 | — | — | US | disclosed |
| US-20210393548-A1 | INHIBITORS OF BUNYAVIRIDAE AND USES THEREOF | SAINT LOUIS UNIVERSITY (US) | 2021-12-23 | — | — | US | disclosed |
| US-20210393548-A1 | INHIBITORS OF BUNYAVIRIDAE AND USES THEREOF | SAINT LOUIS UNIVERSITY (US) | 2021-12-23 | — | — | US | disclosed |
| US-10550084-B2 | Substituted 1-hydroxy-pyridin-2(1H)-ones, and methods of making and using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-02-04 | — | — | US | disclosed |
| US-10550084-B2 | Substituted 1-hydroxy-pyridin-2(1H)-ones, and methods of making and using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-02-04 | — | — | US | disclosed |
| US-20190169128-A1 | SUBSTITUTED 1-HYDROXY-PYRIDIN-2(1H)-ONES, AND METHODS OF MAKING AND USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-06-06 | — | — | US | disclosed |
| US-20190169128-A1 | SUBSTITUTED 1-HYDROXY-PYRIDIN-2(1H)-ONES, AND METHODS OF MAKING AND USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393548-A1 | INHIBITORS OF BUNYAVIRIDAE AND USES THEREOF | HAVCR2, REN, CTSE | MEN1 4771/4885KMT2A 3616/4885THRB 4404/4885 |
| US-20250009686-A1 | INHIBITORS OF BUNYAVIRIDAE AND USES THEREOF | HAVCR2, REN, CTSE | MEN1 4771/4885KMT2A 3616/4885THRB 4404/4885 |
| US-10550084-B2 | Substituted 1-hydroxy-pyridin-2(1H)-ones, and methods of making and using same | RNASEH1, RNASE1, RNASEL | MEN1 1891/4885KMT2A 1917/4885THRB 3721/4885 |
| US-12121500-B2 | Inhibitors of Bunyaviridae and uses thereof | HAVCR2, REN, CTSE | MEN1 4770/4885KMT2A 3548/4885THRB 4452/4885 |
| US-12357589-B2 | Inhibitors of Bunyaviridae and uses thereof | HAVCR2, REN, CTSE | MEN1 4770/4885KMT2A 3548/4885THRB 4452/4885 |
| US-20190169128-A1 | SUBSTITUTED 1-HYDROXY-PYRIDIN-2(1H)-ONES, AND METHODS OF MAKING AND USING SAME | RNASEH1, RNASE1, RNASEL | MEN1 1891/4885KMT2A 1917/4885THRB 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.